Increased Approval Speed Under User Fee System Created $11 Bil.-$13 Bil. In Sales, Economist Tells BIO
This article was originally published in The Pink Sheet Daily
Executive Summary
The increased speed of the drug review process as a result of FDA's user fee system has had a value of $11 bil.-$13 bil. in drug sales, health economist Tomas Philipson (University of Chicago) said June 21
You may also be interested in...
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
FDA Risk Communication Research May Follow Critical Path To Avoid OMB
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts